These data show that the TGR5 signaling pathway is critical in regulating intestinal GLP-1 secretion in vivo and suggest that pharmacological targeting of TGR5 may constitute a promising treatment of metabolic disorders [108]. The gene discussed is GPBAR1; the disease is metabolic disease.